WO2023187561 - 2-[(2-OXO-4-PHENYL-2H-CHROMEN-7-YL)OXY] PROPANAMIDO DERIVATIVES
National phase entry:
Publication Number
WO/2023/187561
Publication Date
05.10.2023
International Application No.
PCT/IB2023/052886
International Filing Date
23.03.2023
Title **
[English]
2-[(2-OXO-4-PHENYL-2H-CHROMEN-7-YL)OXY] PROPANAMIDO DERIVATIVES
[French]
DÉRIVÉS DE 2-[(2-OXO-4-PHÉNYL-2H-CHROMEN-7-YL)OXY] PROPANAMIDO
Applicants **
LUNELLA BIOTECH, INC.
Inventors
LISANTI, Michael P.
SOTGIA, Federica
KANGASMETSA, Jussi
DI PISA, Filippo
Priority Data
63/325,360
30.03.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2842 | |
| EPO | Filing, Examination, Granting | 18827 | |
| Japan | Filing, Examination, Granting | 2513 | |
| South Korea | Filing, Examination, Granting | 2822 | |
| USA | Filing, Examination, Granting | 7740 |
Total:
34,744
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed are 2-[(2-Oxo-4-phenyl-2H-chromen-7-yl)oxy]propanamido derivatives, wherein at least one of R1 to R4 bears an amido group. These derivatives may be used to target and eliminate cancer stem cells, and may be used as therapeutic agents for the treatment of cancer, including reducing the likelihood of and/or preventing tumor recurrence and metastasis. The compounds disclosed herein have demonstrated inhibition of tumorsphere forming capacity, migration and sternness-related signaling in cancer stem cells. These properties result from selective inhibiting of mitochondrial transcription targeting mitochondrial RNA polymerase (POLRMT) in cancer cells. Formula (II)[French]
Sont divulgués des dérivés de 2-[(2-oxo-4-phényl-2H-chromén-7-yl)oxy]propanamido, au moins l'un de R1 à R4 portant un groupe amido. Ces dérivés peuvent être utilisés pour cibler et éliminer des cellules souches cancéreuses, et peuvent être utilisés en tant qu'agents thérapeutiques pour le traitement du cancer, comprenant la réduction de la probabilité et/ou la prévention de la récurrence tumorale et de la métastase. Les composés selon l'invention ont démontré l'inhibition de la capacité de formation de sphère tumorale, de la migration et de la signalisation liée à au caractère souche dans des cellules souches cancéreuses. Ces propriétés résultent d'une inhibition sélective de la transcription mitochondriale ciblant l'ARN polymérase mitochondriale (POLRMT) dans des cellules cancéreuses. Formule (II)